ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Monday, 16 November 2026 NSE & BSE filings, as they land
ALFA News Straight from the exchange filing
Regulatory Approval

Alembic Pharma Receives USFDA Approval for Binimetinib with 180-Day Exclusivity

Alembic Pharmaceuticals has received final USFDA approval for its Binimetinib Tablets (15 mg and 45 mg), securing 180 days of generic drug exclusivity. The approval targets a US market estimated at US$ 282 million for the treatment of specific melanoma and lung cancer mutations.

Scientist focused on writing notes amidst laboratory glassware and a microscope. Stock photo illustrating Alembic Pharmaceuticals' regulatory approval story.
Photo: Gustavo Fring / Pexels
Key numbers
US Market Size $282 MnIQVIA Estimates
Market Cap ₹20,248.95 CrMid Cap
P/E TTM 23.99Sector: 43.74
1-Year Return 12.38%Price Performance

Key highlights

  • Final USFDA approval received for Binimetinib Tablets in 15 mg and 45 mg strengths
  • Secured 180 days of generic drug exclusivity as a first-to-file applicant
  • Targeting a US market size of approximately US$ 282 million as of September 2026
  • Therapeutically equivalent to the reference drug Mektovi by Array BioPharma Inc.
  • Cumulative USFDA approvals for the company now stand at 248 products

Strategic Approval for High-Value Oncology Generic

Alembic Pharmaceuticals Limited has secured final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Binimetinib Tablets. The approval covers the 15 mg and 45 mg strengths, which serve as a kinase inhibitor indicated for use in combination with encorafenib.

This combination therapy is used to treat adult patients with unresectable or metastatic melanoma or metastatic non-small cell lung cancer (NSCLC) that exhibits a BRAF V600E or V600K mutation. The product is a generic version of Mektovi Tablets, originally developed by Array BioPharma Inc., marking a key addition to Alembic's specialized oncology portfolio.

Exclusivity Status and Market Opportunity

  • Alembic was one of the first ANDA applicants for the 15 mg dose and the sole first applicant for the 45 mg strength.
  • The company is eligible for 180 days of generic drug exclusivity for both approved strengths.
  • IQVIA data estimates the market size for Binimetinib tablets at US$ 282 million for the twelve months ending September 2026.
  • The approval follows a Paragraph IV certification, indicating a challenge to existing patents for the reference drug.
  • This launch contributes to the company's total count of 230 final USFDA approvals to date.
Alembic Pharmaceuticals · share price, past month

Strengthening US Portfolio Amid Robust Financial Growth

This regulatory milestone coincides with a period of significant financial expansion for the company. For the quarter ended September 30, 2026, Alembic reported a 36.3% year-on-year increase in operating revenue to ₹2,603.48 crore, while net profit grew 81.5% to ₹335.17 crore. The company maintains an operating profit margin of 21.64%, significantly higher than the 16.5% recorded four quarters ago.

On November 4, 2026, management raised its consolidated revenue growth guidance for FY27 to 20-25% and highlighted a pipeline of over 30 generic products planned for the US market over the next 18 months.

What to watch next

  • Commercial launch of Binimetinib tablets in the US market to utilize the 180-day exclusivity period
  • Execution of the 30+ generic product US pipeline guided by management on 04 Nov 2026
  • Initial launches under the DifGen Pharmaceuticals collaboration expected to commence in FY28
  • Next quarterly financial results announcement scheduled for early February 2027
Alembic Pharmaceuticals · financial snapshot
Share price₹1030.15
Market capitalisation₹20,248.95 Cr
Revenue (annual)₹7,344.90 Cr
Net profit (annual)₹674.77 Cr
Revenue (latest quarter)₹2,603.48 Cr+21.11% vs previous quarter
Net profit (latest quarter)₹335.17 Cr+93.66% vs previous quarter
P/E (TTM)23.99×Sector 43.74×
Promoter holding69.87%0.00% QoQ
FII holding4.55%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

Exchange filing by Alembic Pharmaceuticals Limited announcing USFDA final approval for Binimetinib Tablets. Market figures from a third-party data provider.

Read the filing ↗
All Alembic Pharmaceuticals filings and newsView all → Every Alembic Pharmaceuticals announcement on ALFA FilingsSee filings →

More from Alembic Pharmaceuticals

All →

More in Approvals

All →